Integra LifeSciences Holdings Corporation’s (IART) growth in the third quarter is driven by sales growth within its Codman Specialty Surgical (“CSS”) arm despite ongoing supply challenges and temporary shipping holds. The company’s strong focus on portfolio optimization is encouraging. Meanwhile, headwinds such as a dull macro environment and weak liquidity position pose concerns for Integra’s operations.In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 39.1% against the industry’s 14.7 ...

Core Insights - Integra LifeSciences Holding Corporation (IART) published a study showing significant cost savings when switching from fibrin glue to DuraSeal Polyethylene Glycol (PEG) hydrogel in surgeries across five major European countries, with average savings ranging from €419 to €1,279 per patient and an overall cost reduction of approximately 22% in Belgium, France, Germany, and the UK, and 15% in Italy [1][2][5][6] Company Performance - Following the announcement of the study, IART shares experienced a decline of 6.1%, closing at $23.31, although the development is expected to enhance the international business of the Codman Specialty Surgical segment, which is gaining traction in global neurosurgery [3] - Integra's current market capitalization stands at $1.91 billion, with a projected 4.6% increase in sales for 2024 compared to the previous year, and an earnings beat of 1.41% on average over the last four quarters [4] Study Details - The economic analysis was based on a peer-reviewed observational study involving 200 patients, indicating that PEG hydrogel is more clinically effective than fibrin glue in preventing cerebrospinal fluid (CSF) leaks after posterior cranial fossa surgeries, potentially leading to reduced hospital costs [6][5] - The study was published in the Journal of Comparative Effectiveness Research in February 2024, reinforcing the company's focus on neuro access and repair strategies [2][7] Industry Outlook - The global cerebrospinal fluid management market was valued at $0.67 billion in 2021 and is projected to grow at a CAGR of 4.4% by 2031, driven by increasing incidences of neurological diseases and innovations in the medical device sector [8] Recent Developments - Integra's third-quarter 2024 financial report indicated that both revenue and earnings exceeded consensus estimates, and the company is implementing a compliance master plan to meet robust market demand [9] - Over the past three months, IART shares have increased by 6.6%, contrasting with a 1.8% decline in the broader industry [10]

PRINCETON, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the publication of a new economic study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five European countries.”1 The purpose of this evaluation was to assess the budget-impact of switching patient treatment from fibrin glue to DuraSeal Polyethylene Glycol (PEG) hydrogel in five major Eur ...

Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 41 cents for the third quarter of 2024, a 46.1% plunge year over year. The metric, however, surpassed the Zacks Consensus Estimate by 5.1%.The adjustment excludes the impact of certain non-recurring charges like structural optimization charges, the Boston recall/Braintree transition and EU Medical Device Regulation charges among others.GAAP loss per share in the third quarter was 14 cents against GAAP EPS of 24 c ...

Integra LifeSciences (IART) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.13%. A quarter ago, it was expected that this medical device maker would post earnings of $0.62 per share when it actually produced earnings of $0.63, delivering a surprise of 1.61%.Over the last four quarte ...

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), a leading global medical technology company, today announced that its board of directors has appointed Mojdeh Poul as the new president and chief executive officer, effective January 6, 2025. Ms. Poul will also join the Integra board when she assumes the role. She will succeed Jan De Witte, who will remain president and CEO until January 6, 2025. Stuart Essig will remain executive chairman of Integra ...

PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, November 4, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to partic ...

Integra LifeSciences Holdings Corporation (IART) is well-poised to grow in the coming quarter, driven by healthy sales growth within its Tissue Technologies business despite product recall and manufacturing pause in Boston. The strong performance of the company's Codman Specialty Surgical (CSS) arm is encouraging. Meanwhile, headwinds such as a dull macro environment and currency fluctuations pose concerns for Integra's operations. In the past year, this Zacks Rank #3 (Hold) stock has lost 55.1% against the ...

PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer, will present at the Wells Fargo Healthcare conference on September 4, 2024 at 1:30pm ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciences At Integra Li ...

ESG Report Highlights - Integra LifeSciences issued its latest ESG report, highlighting the company's 2023 ESG performance and ongoing efforts against the ESG strategy and roadmap established three years ago [1] - The company's president and CEO emphasized the importance of innovating treatment pathways to advance patient outcomes and set new standards of care [2] - Integra's ESG report includes highlights in key areas: Environmental, Social, and Governance [2] Environmental Initiatives - Recalculated Scope 1, 2, and 3 emissions and partnered with an external consultant to conduct energy assessments at highest energy usage locations to identify energy reduction opportunities and improve greenhouse gas footprint [2] Social Initiatives - Bolstered diversity and inclusion efforts by adding a new employee resource group [2] - Focused on early-in-career talent by providing support and hands-on experience to diverse college students and graduates [2] Governance Initiatives - Revised Code of Conduct and continued to strengthen anti-bribery and corruption program through ongoing training curriculums and programs [2] Alignment with External Guidelines - Integra prepared its ESG report in alignment with external guidelines and measurement frameworks, including the Global Reporting Index and the Sustainability Accounting Standards Board Index [2] Company Overview - Integra LifeSciences is driven by its purpose of restoring patients' lives and innovates treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care [4] - The company offers a comprehensive portfolio of high quality, leadership brands [4]